Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

TIRCON · Treat Iron-Related Childhood-Onset Neurodegeneration

FP7Status: CLOSED1 November 201131 October 2015EU funding €5,215,220

Neurodegeneration with brain iron accumulation (NBIA) is a heterogeneous group of rare hereditary neurodegenerative disorders characterized by high levels of brain iron. The most common form is pantothenate kinase-associated neurodegeneration (PKAN). Classic PKAN and most other NBIA cases are characterised by early childhood onset and rapid progression. Currently, there is no proven therapy to halt or reverse PKAN or any other NBIA. This is especially unfortunate as both the iron accumulation in NBIA and the biochemical defect in PKAN are predicted to be amenable to drug-based treatment. Thus, the current absence of clinical trials is not due to lack of therapeutic options but to rarity of the disease, lack of patient registries and fragmentation of therapeutic research worldwide. For example, the iron-chelating drug deferiprone has been administered to PKAN patients on an individual basis or in pilot trials, both precluding firm conclusions about its efficacy. With TIRCON, we will address this urgent and unmet need for NBIA/PKAN therapy with an ambitious and highly collaborative plan that leverages worldwide expertise. We propose a large investigator-driven randomized clinical trial of deferiprone in PKAN, bringing together leading centres and patient advocacy groups from Europe and the US to reach the required patient cohort size. In addition, together with a European SME, we propose to pursue preclinical development of pantethine and its derivatives which have shown promising efficacy in a Drosophila PKAN model. To facilitate future research, we will develop a harmonized patient registry and biomaterial bank to allow for natural history studies and biomarker development, two critical needs in NBIA research. TIRCON partners, apart from their unique clinical and basic science expertise in NBIA, have longstanding experience in investigator-driven and industry-driven randomized clinical trials. Importantly, they have been closely collaborating in recent years.

Consortium · 13 organisations

coordinator

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

DE · €1,346,708

participant

NBIA DISORDERS ASSOCIATION

US · €114,720

participant

CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND

US · €248,389

participant

OREGON HEALTH AND SCIENCE UNIVERSITY

US · €281,700

participant

ACADEMISCH ZIEKENHUIS GRONINGEN

NL · €387,000

participant

HOFFNUNGSBAUM EV VEREIN ZUR FORDERUNG DER ERFORSCHUNG UND BEHANDLUNG VON NBIA (VORMALS: HALLERVORDEN-SPATZ-SYNDROM)*TREE OF HOPE EV

DE · €153,600

participant

UNIVERSITY OF NEWCASTLE UPON TYNE

UK · €244,095

participant

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

DE · €844,340

participant

BAYERISCHE FORSCHUNGSALLIANZ BAVARIAN RESEARCH ALLIANCE GMBH

DE · €246,252

participant

INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA

PL · €77,600

participant

ACIES BIO BIOTEHNOLOSKE RAZISKAVE IN RAZVOJ DOO

SI · €394,000

participant

APO-PHARMA INC CORP

CA · €473,383

participant

FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA

IT · €403,433

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.